Back Bay Life Science Advisors

The DNB//Back Bay Partnership’s #MarketUpdate report for the week ending December 20th is now available. Highlights include: ➡️Major indices finished the week down due to the Fed signaling fewer rate cuts than expected next year ➡️ Novo Nordisk’s stock dropped by approximately 20% after its CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the expected 25% ➡️ Merck entered the obesity space by in-licensing preclinical oral GLP-1 candidate from Jiangsu Hansoh Pharmaceutical Group Co., Ltd. for $112.0M upfront and $1.9B in milestones ➡️ DNB//Back Bay acted as the exclusive financial advisor and bookrunner for the business combination of Zelluna Immunotherapy and Ultimovacs ASA and the concurrent private placement of NOK 51.7M ($4.8M USD) ⏹️ The combined company, to be named Zelluna, will prioritize the development of its first-in-class TCR-NK cell therapy technology and explore the potential of the MultiClick platform ➡️ Back Bay recently covered the topic of mega-rounds, as 2024 saw a significant resurgence in mega-round venture financings (venture deals > $100M) from 2023’s slowdown. Over 90 private healthcare companies have raised mega-rounds YTD, with >85% supporting biopharma companies. You can read the article on Back Bay's website, here: https://bit.ly/3DoBEMH Read the full update here: https://bit.ly/4gPuW0y #healthcaremarket #investmentbanking #corporatebanking #marketsinc #markettrends #financing #BBLSA #DNB 

Happy Holidays from all of us at Back Bay Life Science Advisors! 🌟🎄 We’re grateful for the impactful collaborations and groundbreaking innovations that shaped 2024. Wishing everyone a joyful holiday season and a successful year ahead! #HappyHolidays #LifeSciences #InvestmentBanking #Gratitude #BBLSA 

Congratulations to Ultimovacs ASA and Zelluna Immunotherapy on their new agreement! We’re proud to have played a role in this exciting collaboration with our partners DNB and look forward to seeing the impact it will have. #DNB #BBLSA #Investmentbanking #Biotech #Healthcare  

At Back Bay Life Science Advisors, we believe in #givingback to the communities we serve. Recently, we had the privilege of partnering with Cradles to Crayons to support their inspiring mission to #EndClothingInsecurity. Our team gathered for a meaningful day of volunteering, packing clothing and essential items to help children in need. We’re proud to contribute to such a critical cause and are grateful for the opportunity to make a difference. Thank you Cradles to Crayons for the important work you do to support families and children. Learn more about this cause ➡️ https://bit.ly/4gA6L6s #NationalGivingMonth #CorporateSocialResponsibility #CommunityImpact #BBLSA 

The 15th Annual DNB Nordic Healthcare Conference was a resounding success! Our CEO, Jonathan P. Gertler, MD, was honored to deliver the keynote address, sharing insights with healthcare leaders and investors.    A big thank you to the DNB Oslo team for hosting such a meaningful event, fostering impactful connections and discussions within the healthcare community. We’re excited to welcome our partners and many others to the upcoming Nordic-American Healthcare Conference (NAHC), March 2025!    #DNB #BBLSA #HealthcareConference #Networking #NAHC2025  

The DNB//Back Bay Partnership’s #MarketUpdate report for the week ending December 6th is now available. Highlights include: ➡️ US indices ended the week up thanks to a promising jobs reports and investors pricing in an increased likelihood of another rate cut coming out of the Federal Reserve’s meeting in mid-December ➡️ Follow-on offerings had a notably active week with two clinical-stage oncology companies – Revolution Medicines and Janux Therapeutics raising $762.5M and $335.0M each, respectively ➡️ Licensing deals observed an uptick in volume last week, led by Novartis spending $1.0B upfront and $1.9B in milestones for the global rights to PTC’s Phase 2 Huntington's drug candidate PTC518 Read the full update here: https://bit.ly/4faiasC #healthcaremarket #investmentbanking #corporatebanking #marketsinc #markettrends #financing #BBLSA #DNB 

We’re excited to share our latest #whitepaper: Upgrading the Code- RNA Beyond Conventional mRNA. In this comprehensive analysis, #BBLSA experts Jim Grady and Peter Bak, with contributions from Mavra Nasir, explore the development and evolving landscape of coding #RNA technologies. Long before the approval of COVID-19 vaccines, the biopharmaceutical industry recognized #mRNA’s potential as a therapeutic modality. However, the limitations of conventional mRNA have presented challenges in advancing through #clinicaltrials. Now, #innovation is driving the field forward. Researchers and organizations are developing next-generation coding RNA technologies, with over 230 programs—spanning conventional and next-gen coding RNA—progressing toward marketing approval. Read the full white paper here: https://bit.ly/4fefEkS  

We are thrilled to share the selected companies of our first Healthcare Innovation Accelerator! This program is a collaborative effort between DNB//Back Bay, Innovation Norway, Destination Medical Center (DMC), and Mayo Clinic Innovation Exchange. We are excited to welcome Nordic Brain Tech AS, GlucoSet, Induvita AS, Nordiq Products AS, ExAC AS, Deepinsight, RESPINOR AS, and Sensocure AS to New York City for the upcoming Nordic-American Healthcare Conference (NAHC) 2025. Congratulations to these innovative companies! #Innovation #Healthcare #NAHC2025  

Happy Thanksgiving from Back Bay Life Science Advisors! 🍁 As we take time to celebrate this season of #gratitude, we’d like to express our heartfelt thanks to our clients, partners, and colleagues who inspire and support us every day. Wishing you and your loved ones a holiday filled with warmth, gratitude, and joy. #HappyThanksgiving #LifeSciences #Innovation #BBLSA

The DNB//Back Bay Partnership’s #MarketUpdate report for the week ending November 22nd is now available. Highlights include: ➡️ US indices ended the week with minor gains, largely driven by Nvidia’s strong Q3 earnings ➡️ Licensing deals had one of their busiest weeks in Q4 so far with five deals announced, each with a potential aggregate deal value of $500M or more ⏹️ The largest deal was Kyowa Kirin, Inc.- U.S., paying $330M upfront and pledging up to $933M in milestones to split the US profits of Kura Oncology, Inc.’s Phase 2 oral leukemia treatment, in addition to obtaining commercialization rights for the rest of the world ⏹️ Radiopharmaceuticals continues to be one of the hottest modalities within oncology deals this year as Novartis added another program to its pipeline, penning a research collaboration deal worth up to $745M for the rights of an SSTR2-targeting asset from Ratio Therapeutics ➡️ Novartis made headlines with its $1.1B structured acquisition of Kate Therapeutics, providing the Swiss drug maker with gene therapy preclinical programs targeting Duchenne muscular dystrophy (DMD), facioscapulohumeral dystrophy (FSHD), and myotonic dystrophy type 1 (DM1) Read the full update here: https://bit.ly/3AX7ob2 #radiopharmaceuticals #oncology #healthcaremarket #investmentbanking #corporatebanking #marketsinc #markettrends #financing #BBLSA #DNB